Trial · NCT01062230
Bone Effect of Bortezomib in Patients With Relapsed/Refractory Multiple Myeloma
NCT01062230, Phase 2, Terminated, University of Arkansas; results first posted 2015-04-06
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Bone Effect of Bortezomib in Patients With Relapsed/Refractory Multiple Myeloma. Trials, record NCT01062230. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01062230
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Bone Effect of Bortezomib in Patients With Relapsed/Refractory Multiple Myeloma
- NCT number
- NCT01062230
- Status
- Terminated
- Phases
- Phase 2
- Enrollment
- 6 participants, actual
- Lead sponsor
- University of Arkansas
- Conditions
- Multiple Myeloma
- Interventions
- Bortezomib (Velcade)
- First posted
- 2010-02-04
- Last updated
- 2015-04-06
- Results first posted
- 2015-04-06
- Limitations and caveats
- Complete data was not received from the primary institution for all six patients enrolled. Data available is represented.
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Maximum Percent Change From Baseline in Intact Parathyroid Hormone Levels on Day 1 | Baseline and Day 1 | All patients received 0.7 mg/m2 of bortezomib on days 1, 4, 8 and 11 of a 21 day cycle, for maximum of three cycles for an average of 18 months. Intact Parathyroid hormone was measured in patients with relapsed/refractory myeloma for osteoblast activation. Other bone markers were examined using similar methods. |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Maximum Percent Change From Baseline in Intact Parathyroid Hormone Levels on Day 1 | Baseline and Day 1 | % change | NUMBER |
Source ClinicalTrials.gov
Results by group6
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Maximum Percent Change From Baseline in Intact Parathyroid Hormone Levels on Day 1 | All Patients | Subject 1 | 113.5 | % change | |
| Maximum Percent Change From Baseline in Intact Parathyroid Hormone Levels on Day 1 | All Patients | Subject 2 | -9.09 | % change | |
| Maximum Percent Change From Baseline in Intact Parathyroid Hormone Levels on Day 1 | All Patients | Subject 3 | 30.7 | % change | |
| Maximum Percent Change From Baseline in Intact Parathyroid Hormone Levels on Day 1 | All Patients | Subject 4 | -50 | % change | |
| Maximum Percent Change From Baseline in Intact Parathyroid Hormone Levels on Day 1 | All Patients | Subject 5 | 93.6 | % change | |
| Maximum Percent Change From Baseline in Intact Parathyroid Hormone Levels on Day 1 | All Patients | Subject 6 | -53.5 | % change |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | All Patients | 6 | |
| Overall Study | COMPLETED | All Patients | 6 | |
| Overall Study | NOT COMPLETED | All Patients | 0 |
Source ClinicalTrials.gov
Adverse events15
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | hypercalcemia | Metabolism and nutrition disorders | All Patients | 1 | 6 | 1 |
| other | platelets | Blood and lymphatic system disorders | All Patients | 1 | 6 | 1 |
| other | Neuropathy | Nervous system disorders | All Patients | 1 | 6 | 1 |
| other | Creatinine, Serum | Metabolism and nutrition disorders | All Patients | 1 | 6 | 1 |
| other | Low ANC | Blood and lymphatic system disorders | All Patients | 1 | 6 | 1 |
| other | Lymphopenia | Blood and lymphatic system disorders | All Patients | 1 | 6 | 1 |
| other | Fatigue | General disorders | All Patients | 1 | 6 | 1 |
| other | Hypertension | Cardiac disorders | All Patients | 1 | 6 | 1 |
| other | Back Pain | Musculoskeletal and connective tissue disorders | All Patients | 1 | 6 | 1 |
| other | platelets - Thrombocytopenia | Blood and lymphatic system disorders | All Patients | 1 | 6 | 1 |
1 to 10 of 15Source ClinicalTrials.gov
See all 15 adverse eventsAdverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | All Patients | ||
| Total, other adverse events | All Patients | 4 | 6 |
| Total, serious adverse events | All Patients | 0 | 6 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01062230
GET https://conductscience.org/api/trials/v1/NCT01062230/registered